Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Periodontal Infection and Endothelial Dysfunction

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Jorge Hernán Ramírez, Universidad del Valle, Colombia
ClinicalTrials.gov Identifier:
NCT00681564
First received: May 19, 2008
Last updated: March 31, 2014
Last verified: March 2014

May 19, 2008
March 31, 2014
May 2008
March 2011   (final data collection date for primary outcome measure)
Brachial Artery Flow-mediated Dilation [ Time Frame: Baseline; 24 hours post periodontal therapy; 12 weeks post periodontal therapy ] [ Designated as safety issue: No ]
All the assessments of vascular function were performed in the morning, in a temperature controlled room, with participants required to fast for at least 8 hours. Flow-mediated, endothelium dependent vasodilatation of the brachial artery (FMD) was measured using the technique described by Celermajer et al. using the guidelines reported by Coretti et al. FMD was calculated as the percentage of change in the diameter of brachial artery measured 45-60 s after cuff release in relation to the baseline measure (FMD%).
Brachial artery flow-mediated dilation [ Time Frame: Baseline; 24 hours post periodontal therapy; 12 weeks post periodontal therapy ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00681564 on ClinicalTrials.gov Archive Site
  • High-sensitivity C-Reactive Protein [ Time Frame: Baseline; 24 hours post periodontal therapy; 12 weeks post periodontal therapy ] [ Designated as safety issue: No ]
    The fasting plasma hs-CRP concentrations was evaluated using a quantitative solid-phase, chemiluminescent immunometric assay (Immulite 1000, Siemens).
  • Total Cholesterol [ Time Frame: Baseline; 24 hours post periodontal therapy; 12 weeks post periodontal therapy ] [ Designated as safety issue: No ]
  • White Blood Cell Count [ Time Frame: Baseline; 24 hours post periodontal therapy; 12 weeks post periodontal therapy ] [ Designated as safety issue: No ]
  • Subgingival Microbiota [ Time Frame: 12 weeks post-periodontal therapy ] [ Designated as safety issue: No ]
    Polymerase chain reaction (PCR) was used for detection of the three red-complex periodontal pathogens in periodontal pockets: Porphyromonas gingivalis (Pg), Treponema denticola (Td) and Tannerella forsythia (Tf).
  • LDL Cholesterol [ Time Frame: Baseline; 24 hours post periodontal therapy; 12 weeks post periodontal therapy ] [ Designated as safety issue: No ]
  • Endothelial Leukocyte Adhesion Molecule-1 (E-Selectin) [ Time Frame: 12 weeks post periodontal therapy ] [ Designated as safety issue: No ]

    Multiplexed immuno-cytometric assay for the simultaneous measurement of MMP-9, MPO, tPAI-1, E-Selectin, ICAM-1, and VCAM-1 in serum samples (Milliplex® MAP kit, Human Cardiovascular Disease Panel 1, Millipore®).

    Luminex® 200™ IS Total System and xPONENT software were used for data acquisition and analysis.

  • Intercellular Adhesion Molecule 1 (ICAM-1) [ Time Frame: 12 weeks post periodontal therapy ] [ Designated as safety issue: No ]
  • Vascular Cell Adhesion Molecule 1 (VCAM-1) [ Time Frame: 12 weeks post periodontal therapy ] [ Designated as safety issue: No ]
  • Myeloperoxidase (MPO) [ Time Frame: 12 weeks post periodontal therapy ] [ Designated as safety issue: No ]
  • Matrix Metalloproteinase-9 (MMP-9) [ Time Frame: 12 weeks post periodontal therapy ] [ Designated as safety issue: No ]
  • Tissue Plasminogen Activator Inhibitor-1 (tPAI-1) [ Time Frame: 12 weeks post periodontal therapy ] [ Designated as safety issue: No ]
  • high-sensitivity C-Reactive Protein [ Time Frame: Baseline; 24 hours post periodontal therapy; 12 weeks post periodontal therapy ] [ Designated as safety issue: No ]
  • Blood Lipid Profile [ Time Frame: Baseline; 24 hours post periodontal therapy; 12 weeks post periodontal therapy ] [ Designated as safety issue: No ]
  • White Blood Cell Count [ Time Frame: Baseline; 24 hours post periodontal therapy; 12 weeks post periodontal therapy ] [ Designated as safety issue: No ]
  • Periodontopathogenic bacteria in periodontal pockets: a. Polymerase Chain Reaction (P. gingivalis, A. actinomycetemcomitans, D. pneumosintes, and T. forsythia) b. Anaerobic culture [ Time Frame: Baseline; 12 weeks post periodontal therapy ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Periodontal Infection and Endothelial Dysfunction
Impact of Periodontal Therapy on Endothelial Function

The purpose of this study is to determine the effect of periodontal therapy on endothelial function and other biomarkers of cardiovascular disease

Periodontitis is one of the most prevalent chronic diseases and a frequent cause of tooth loss. Accumulation of subgingival dental biofilm in susceptible individuals is associated with an inflammatory host response characterized by the production of Matrix Metalloproteinases, reduction in collagen synthesis, increase in cytokine gene expression, and apoptosis of gingival fibroblasts. Finally, inflammation leads to destruction of periodontal ligament, alveolar bone resorption, and chronic periodontitis.

Periodontitis is associated with increased serum levels of inflammatory cytokines and acute phase reactants. Multiple case-control and cohort studies have suggested that periodontitis is an independent risk factor for cardiovascular events, diabetic end-organ damage, pregnancy complications and respiratory diseases. Recent interventional studies have found that periodontal therapy could increase endothelium-dependent brachial artery flow-mediated dilation.

The purpose of this controlled clinical trial is to determine the effect of periodontal therapy on endothelial function in subjects with moderate to severe chronic periodontitis. Furthermore, the relationship between putative periodontal pathogens and endothelial function will be also evaluated.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Periodontitis
  • Procedure: One-Stage Full-Mouth Disinfection
    • Scaling and root planing, four quadrants in one session
    • Tongue brushing with a 1% chlorhexidine gel (1 minute)
    • Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes)
    • Subgingival chlorhexidine (1%) irrigation in all pockets
    • Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention
    • Basic oral hygiene instructions
    • Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)
  • Procedure: Periodontal care
    • Basic oral hygiene instructions
    • Supragingival plaque removal
  • Experimental: One-Stage Full-Mouth Disinfection
    Scaling and root planing, four quadrants in one session Tongue brushing with a 1% chlorhexidine gel (1 minute) Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes) Subgingival chlorhexidine (1%) irrigation in all pockets Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention Basic oral hygiene instructions Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)
    Intervention: Procedure: One-Stage Full-Mouth Disinfection
  • Active Comparator: Periodontal care
    Basic oral hygiene instructions Supragingival plaque removal
    Intervention: Procedure: Periodontal care

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
102
January 2012
March 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects must be 25 years of age or older
  • Three or more periodontal pockets with a probing depth (PD) > 5mm
  • Have at least 20 natural teeth
  • Provide informed consent and willingness to cooperate with the study protocol

Exclusion Criteria:

  • History of antibiotic use in the previous three months
  • Pregnant or lactating females
  • Treatment with antihypertensive, antilipemic, antiarrhythmic, and other cardiovascular drugs
  • Systemic diseases such as diabetes, HIV/AIDS, liver disease, chronic renal failure, tuberculosis, and autoimmune diseases
  • Previous history of cardiovascular disease: Acute myocardial infarct, stable angina, unstable angina, heart failure, atrial fibrillation, atrioventricular block, peripheral vascular disease, cerebrovascular accident
  • Patients who received periodontal treatment within the last 3 months
  • Patients who require antibiotic prophylaxis before examination or treatment
  • Patients with mental retardation and dementia
Both
25 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Colombia
 
NCT00681564
COLCIENCIAS 110634319239
Yes
Jorge Hernán Ramírez, Universidad del Valle, Colombia
Universidad del Valle, Colombia
Not Provided
Principal Investigator: Adolfo Contreras, DDS, MS, PhD Universidad del Valle
Principal Investigator: Jorge H Ramirez, MD, MS Universidad del Valle
Universidad del Valle, Colombia
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP